LAA-START SIGNED
Left Atrial Appendage Electrical Isolation via Bio-photonic Optical Confirmation to Treat Persistent Atrial Fibrillation
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0LAA-START project word cloud
Explore the words cloud of the LAA-START project. It provides you a very rough idea of what is the project "LAA-START" about.
Project "LAA-START" data sheet
The following table provides information about the project.
| Coordinator |
AURIGEN MEDICAL LIMITED
Organization address contact info |
| Coordinator Country | Ireland [IE] |
| Total cost | 5˙012˙590 € |
| EC max contribution | 2˙999˙998 € (60%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-EIC-FTI-2018-2020 |
| Funding Scheme | IA |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-01-01 to 2020-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | AURIGEN MEDICAL LIMITED | IE (DUBLIN) | coordinator | 1˙115˙458.00 |
| 2 | TELEFLEX MEDICAL EUROPE LIMITED | IE (ATHLONE CO. WESTMEATH) | participant | 953˙470.00 |
| 3 | UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK | IE (Cork) | participant | 516˙948.00 |
| 4 | MEDIBRANE LTD | IL (ROSH HAAYIN) | participant | 334˙600.00 |
| 5 | CESKE VYSOKE UCENI TECHNICKE V PRAZE | CZ (PRAHA) | participant | 79˙522.00 |
Map
Project objective
Atrial Fibrillation (AF) is an irregular heartbeat caused by abnormal electrical activity in the heart, that can lead to blood clots with high risk of stroke and heart failure. There are 10.7 million AF patients across Europe and the US, 3.6 million are classified as having Persistent AF (PAF), they are highly symptomatic and medication resistant. Surgical electrical therapy (catheter ablation) destroys heart tissue causing the abnormal electrical pulses. For PAF patients, this works only 30% of the time. Approximately 72% of PAF patients require at least one redo procedure, amounting to €13.5 billion in wasted healthcare costs. Success rates are doubled if electrical activity in a part of the heart “the Left Atrial Appendage” (LAA), is shut down. But this increases stroke risk from blood clots as the LAA is now incapable of muscle contraction to maintain blood flow. LAA implants, “occlusion devices” fit across the opening of the LAA to filter the blood and prevent clots from entering the blood stream. However, fitting an occlusion device during the same procedure as LAA electrical isolation doubles procedure time (to 7 hours) making it non-financially viable for health services and too high risk for patients. AuriGen Medical have developed a unique, minimally invasive cardiac implant which permanently electrically and mechanically isolates the LAA in a one-shot procedure: treating both the stroke and arrhythmia risk associated with PAF with no increase in surgery time. This multi-partner FTI project will complete product development in line with the regulatory development pathway for medical devices for first in human safety and efficacy clinical studies required for CE certification and contributing to FDA clinical data requirements. The total market opportunity is $5bn/yr market opportunity across the EU and US. AuriGen will enter the market directly in the initial target European markets (Germany, France, Italy and UK) during Q3 2020.
Deliverables
| Clinical Affairs Director Appointed | Other | 2020-04-02 09:09:54 |
| Biostatistician Appointed | Other | 2020-04-02 09:10:11 |
| Manufacturing Engineer Appointed | Other | 2020-04-02 09:10:03 |
Take a look to the deliverables list in detail: detailed list of LAA-START deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LAA-START" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LAA-START" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)
PAV-DT (2019)
A disruptive technology that enables low cost real-time monitoring of road pavement condition by any ordinary vehicle circulating on the road, and automatically designs plans for predictive maintenance.
Read More